Burning Rock Biotech (BNR) investor relations material

Executive summary

• Extended leadership in NGS-based precision oncology, expanding from late-stage to earlier-stage patients and launching new businesses in early detection and biopharma.

• Achieved sequential revenue recovery in Q2 2026 after a volatile Q1, with new products entering regulatory priority review channels.

• Achieved regulatory milestones with multiple products entering priority and special review channels in China.

• Demonstrated continued operational efficiency, with revenue growth in the in-hospital channel and improved gross margins.

• Management anticipates sustainable long-term growth as new product registrations are expected in coming quarters.

Financial highlights

• Q2 2026 revenues were RMB 134.8 million, down 9% year-over-year but up 25% sequentially from the previous quarter.

• In-hospital revenues grew 7.4% year-over-year and 27% sequentially, now representing 53% of total revenue.

• Gross profit margin remained stable at 73% year-over-year; gross profit was RMB 97.8 million, a 9.5% decrease year-over-year.

• Operating expenses decreased 3.2% year-over-year, reflecting disciplined cost control.

• Cash, cash equivalents, and restricted cash stood at RMB 419 million as of June 30, 2026.

Outlook and guidance

• Ongoing transition to in-hospital business expected to drive further revenue growth and margin improvement.

• Management expects new product approvals and regulatory milestones to drive top-line growth in future quarters.

• Continued focus on cost savings and operational efficiency to support path to profitability.